logo

CDNA

CareDx·NASDAQ
--
--(--)
--
--(--)
1.65 / 10
Underperform

CareDx's fundamental framework scores only 1.6 out of 10, indicating poor quality. Key concerns include negative Asset-MV (-0.5066) and Cash-MV (0.3084) factors, a low Net income-Revenue ratio (-2.2449), and a negative ROA (-3.7355). Although Profit-MV (0.4743) is positive, the overall fundamental picture remains challenging, with historical back-tests showing negative returns for most factors. This suggests limited intrinsic value and higher operational risks.

Fundamental(1.65)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.16
Score1/3
Weight12.09%
1M Return-1.58%
ROA (%)
Value-3.74
Score2/3
Weight2.25%
1M Return-0.25%
Net cash flow from operating activities / Operating revenue (%)
Value7.62
Score1/3
Weight18.65%
1M Return-2.56%
Profit-MV
Value0.47
Score2/3
Weight-28.55%
1M Return2.92%
Net income-Revenue
Value-2.24
Score2/3
Weight17.79%
1M Return-2.32%
Cash-UP
Value0.88
Score2/3
Weight31.31%
1M Return-4.39%
Annualized net profit margin on total assets (%)
Value-4.98
Score2/3
Weight2.25%
1M Return-0.25%
Asset-MV
Value-0.51
Score1/3
Weight-3.00%
1M Return0.36%
Cash-MV
Value0.31
Score1/3
Weight34.47%
1M Return-5.27%
Net profit / Total profit (%)
Value99.57
Score2/3
Weight12.76%
1M Return-1.55%
Is CDNA fundamentally strong?
  • CDNA scores 1.65/10 on fundamentals and holds a Premium valuation at present. Backed by its -5.00% ROE, 19.68% net margin, 14.21 P/E ratio, 3.22 P/B ratio, and 147.04% earnings growth, these metrics solidify its Underperform investment rating.